<DOC>
	<DOCNO>NCT00593060</DOCNO>
	<brief_summary>In study , investigational drug , temsirolimus , combine cetuximab , biologic agent use treatment colorectal cancer . Cetuximab combination temsirolimus may effective treating advance colorectal cancer cetuximab alone . The purpose research study try define high dose cetuximab use safely combination temsirolimus treat advance colorectal cancer progress standard therapy .</brief_summary>
	<brief_title>Temsirolimus ( CCI-770 , Torisel ) Combined With Cetuximab Cetuximab-Refractory Colorectal Cancer</brief_title>
	<detailed_description>- Because study determine high dose cetuximab safely give temsirolimus , group 3 participant treat gradually increase dos cetuximab . Each group 3 participant must complete 4 week ( 1 cycle ) treatment follow group 3 participant start treatment high dose . - Cetuximab administer intravenously 7 day treatment cycle begin . Participants receive cetuximab infusion every week treatment cycle ( day 1 , 8 , 15 , 22 ) along temsirolimus . Temsirolimus also give intravenously . - As precaution , participant pre-medicated Benadryl/diphenhydramine help prevent allergic reaction . - During study participant weekly clinical visit . Each clinic visit last approximately 2-3 hour . During clinic visit , follow test procedure perform : Physical exam ; vital sign ; blood test . A CT scan perform every 2 cycle ( 8 week ) . - Pharmacokinetic ( PK ) blood sample take various point study . For PK sample , take 1 teaspoon blood . There total 22 tube blood take PK study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Previously treat metastatic colorectal adenocarcinoma , histologically proven . Subjects must previously receive evidence progression cetuximab , bevacizumab , 5FU , irinotecan , oxaliplatin , demonstrated intolerance agent ( except cetuximab ) . Measurable disease RECIST criterion ECOG Performance Status 0 1 . Male female , 18 year age older . Life expectancy great equal 12 week . At least 2 week elapse previous anticancer therapy AND resolution skin rash relate prior treatment epidermal growth factor receptor inhibitor . Lab value within range outline protocol Diagnosis second malignancy within last 3 year , except adequately treat basal cell carcinoma squamous cell skin cancer . Ongoing cardiac dysrhythmias NCI CTCAE grade &gt; /=2 , atrial fibrillation , QTc prolongation &gt; 450msec male &gt; 470 msec female . Known immunodeficiency disorder active infection require treatment Pregnancy breastfeed Brain metastasis , spinal cord compression , carcinomatous meningitis , leptomeningeal disease Prior radiation therapy major surgery within 2 week study entry Prior radiation therapy &gt; 25 % bone marrow Treatment experimental alternative therapy course trial History hypersensitivity polysorbate cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Temsirolimus</keyword>
	<keyword>cetuximab</keyword>
	<keyword>metastatic disease</keyword>
</DOC>